{"id":"rimegepant-75mg-daily-dosing","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)","action":"Avoid","effect":"Increased rimegepant exposure"},{"drug":"P-glycoprotein inducers (e.g., rifampin, St. John's Wort)","action":"Avoid","effect":"Decreased rimegepant exposure"},{"drug":"CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","action":"Avoid","effect":"Increased rimegepant exposure"},{"drug":"CYP3A4 inducers (e.g., rifampin, St. John's Wort)","action":"Avoid","effect":"Decreased rimegepant exposure"},{"drug":"Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)","action":"Avoid","effect":"Increased risk of adverse reactions"},{"drug":"Strong CYP3A4 inducers (e.g., rifampin, St. John's Wort)","action":"Avoid","effect":"Decreased efficacy"}],"commonSideEffects":[{"effect":"Nasopharyngitis","drugRate":"5.6%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":232,"totalAffected":13,"trialsReporting":1},{"effect":"COVID-19","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":232,"totalAffected":0,"trialsReporting":1}],"contraindications":["Patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or to any of its components."],"specialPopulations":{"Pregnancy":"Women of childbearing potential were required to have a negative pregnancy test and use acceptable effective methods of contraception consistently during the study.","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"},"seriousAdverseEvents":[{"event":"Crohn's disease","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Oesophageal carcinoma","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Status migrainosus","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.4%"},{"event":"Appendicitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Infected cyst","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Urinary tract infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Post procedural haemorrhage","detail":"Injury, poisoning and procedural complications. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Liver function test abnormal","detail":"Investigations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Back pain","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Costochondritis","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T22:52:54.515452+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T22:53:03.193977+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2364629/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T22:52:47.836599+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:53:04.549691+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T22:52:46.882730+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:53:04.549685+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:53:04.549676+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:34:43.888228+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:53:04.549384+00:00"}},"allNames":"rimegepant 75mg daily dosing","offLabel":[],"timeline":[],"aiSummary":"Rimegepant 75mg daily dosing, developed by Pfizer, holds a significant market position as a calcitonin gene-related peptide receptor antagonist, targeting patients with moderate-to-severe migraine attacks. Its competitive advantage lies in its unique mechanism of action, which differentiates it from milder treatments like acetaminophen and NSAIDs, and provides an alternative to triptans, antidepressants, and antiepileptics. A key risk is the lack of clinical trial data to support its efficacy and safety, which may limit its adoption and regulatory approvals. The pipeline outlook remains uncertain due to the requirement for a PD-L1 companion diagnostic for several indications, potentially delaying further development and market expansion.","brandName":"Rimegepant 75mg daily dosing","ecosystem":[],"isGeneric":true,"mechanism":{"target":"calcitonin gene-related peptide receptor","novelty":"first-in-class","modality":"small molecule","drugClass":"calcitonin gene-related peptide receptor antagonist","explanation":"Rimegepant works by binding to the calcitonin gene-related peptide receptor, which is a key player in the pathophysiology of migraine. This binding action inhibits the release of pro-inflammatory peptides, such as calcitonin gene-related peptide (CGRP), that are involved in the development of migraine symptoms. By reducing the levels of these peptides, rimegepant helps to alleviate migraine symptoms and prevent future attacks.","oneSentence":"Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides.","technicalDetail":"Rimegepant is a small molecule that selectively binds to the calcitonin gene-related peptide receptor, thereby inhibiting the activity of CGRP and other pro-inflammatory peptides. This mechanism of action is thought to be responsible for the drug's efficacy in treating and preventing migraine attacks. Rimegepant's pharmacological profile has been characterized in detail, and it has been shown to have a favorable safety and tolerability profile in clinical trials."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":0,"chemblId":"CHEMBL2364629","maxPhase":"4.0","chirality":1,"parenteral":false,"availability":1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":true},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"fdaRecalls":[],"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rimegepant-75mg-daily-dosing","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:34:51.767734+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Acetaminophen","company":"Various","advantage":"Milder attacks"},{"name":"Nonsteroidal anti-inflammatory drugs (NSAIDs)","company":"Various","advantage":"Milder attacks"},{"name":"Migraine-specific triptans","company":"Various","advantage":"Moderate-to-severe attacks"},{"name":"Antidepressants","company":"Various","advantage":"Preventive treatment"},{"name":"Antiepileptics","company":"Various","advantage":"Preventive treatment"},{"name":"Beta-blockers","company":"Various","advantage":"Preventive treatment"},{"name":"Botulinum toxin A","company":"Various","advantage":"Preventive treatment"},{"name":"Topiramate","company":"Janssen Pharmaceuticals","advantage":"Preventive treatment"},{"name":"Gabapentin","company":"Pfizer","advantage":"Preventive treatment"},{"name":"Venlafaxine","company":"Pfizer","advantage":"Preventive treatment"},{"name":"Desvenlafaxine","company":"Pfizer","advantage":"Preventive treatment"},{"name":"Duloxetine","company":"Eli Lilly and Company","advantage":"Preventive treatment"},{"name":"Milnacipran","company":"Forest Laboratories","advantage":"Preventive treatment"}],"genericName":"rimegepant-75mg-daily-dosing","indications":{"approved":[{"name":"Acute treatment of migraine attacks with or without aura in adults","regulator":"FDA"},{"name":"Prevention of migraine attacks in adults","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05217927","phase":"PHASE4","title":"Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens","status":"","acronym":null,"sponsor":"Pfizer","isPivotal":false,"primaryCI":"[-1.22, -0.01]","primaryHR":"-0.6","enrollment":1415,"indication":"Migraine","endpointCount":20,"primaryPValue":"=0.0220","completionDate":"","primaryEndpoint":"Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)"}],"_emaApprovals":[{"date":"","name":"Rimegepant 75mg daily dosing","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL2364629","moleculeType":"Small molecule","molecularWeight":"1221.26"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2364629"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[{"actionType":"ANTAGONIST","targetChemblId":"CHEMBL3798","mechanismComment":"Therapeutic mechanism not fully elucidated.","mechanismOfAction":"Calcitonin gene-related peptide type 1 receptor antagonist"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[{"nctId":"NCT05217927","groups":[{"id":"FG000","title":"Double Blind (DB) Rimegepant/ Placebo/ Open Label (OL) Rimegepant","description":"Participants received rimegepant (RMG) 75 mg, orally disintegrating tablets (ODT), once every other day (EOD) alternating with matching placebo dosed EOD for 12 weeks in the double blind treatment (DB"},{"id":"FG001","title":"DB Rimegepant/OL Rimegepant","description":"Participants received RMG 75 mg ODT, once daily for 12 weeks in the DBT phase. Eligible participants continued to receive RMG 75 mg ODT once daily for 12 weeks in the OLE phase. Participants were foll"},{"id":"FG002","title":"DB Placebo/OL Rimegepant","description":"Participants received matching placebo for RMG 75 mg ODT once daily for 12 weeks, in the DBT phase. Eligible participants received RMG 75 mg ODT once daily for 12 weeks in the OLE phase. Participants "}],"acronym":null,"periods":[{"title":"DBT Phase","milestones":[{"type":"STARTED","counts":{"FG000":"234","FG001":"232","FG002":"233"}},{"type":"Treated","counts":{"FG000":"232","FG001":"229","FG002":"231"}},{"type":"COMPLETED","counts":{"FG000":"204","FG001":"209","FG002":"208"}},{"type":"NOT COMPLETED","counts":{"FG000":"30","FG001":"23","FG002":"25"}}],"dropWithdraws":[{"type":"Adverse Event","counts":{"FG000":"7","FG001":"2","FG002":"5"}},{"type":"Lack of Efficacy","counts":{"FG000":"1","FG001":"0","FG002":"0"}},{"type":"Lost to Follow-up","counts":{"FG000":"0","FG001":"2","FG002":"0"}},{"type":"Non-compliance","counts":{"FG000":"1","FG001":"0","FG002":"0"}},{"type":"Pregnancy","counts":{"FG000":"0","FG001":"0","FG002":"1"}},{"type":"Protocol Violation","counts":{"FG000":"0","FG001":"2","FG002":"1"}},{"type":"Protocol-specified withdrawal criterion met","counts":{"FG000":"4","FG001":"6","FG002":"5"}},{"type":"Withdrawal of consent","counts":{"FG000":"8","FG001":"5","FG002":"7"}},{"type":"Other","counts":{"FG000":"7","FG001":"3","FG002":"4"}},{"type":"Randomized, not treated","counts":{"FG000":"2","FG001":"3","FG002":"2"}}]},{"title":"OLE Phase","milestones":[{"type":"STARTED","counts":{"FG000":"182","FG001":"196","FG002":"195"}},{"type":"COMPLETED","counts":{"FG000":"170","FG001":"187","FG002":"183"}},{"type":"NOT COMPLETED","counts":{"FG000":"12","FG001":"9","FG002":"12"}}],"dropWithdraws":[{"type":"Adverse Event","counts":{"FG000":"4","FG001":"1","FG002":"1"}},{"type":"Extension phase eligibility failure","counts":{"FG000":"1","FG001":"0","FG002":"0"}},{"type":"Lost to Follow-up","counts":{"FG000":"1","FG001":"2","FG002":"1"}},{"type":"Non-compliance","counts":{"FG000":"0","FG001":"0","FG002":"1"}},{"type":"Other","counts":{"FG000":"3","FG001":"5","FG002":"4"}},{"type":"Withdrawal of consent","counts":{"FG000":"3","FG001":"1","FG002":"5"}}]}],"recruitment":"","preAssignment":"A total of 1415 participants were enrolled in the study, of which 716 failed screening and 699 participants were randomized. Of the 699 randomized participants, 692 participants received the study intervention."}],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"-0.6","nctId":"NCT05217927","phase":"PHASE4","pValue":"=0.0220","ciLower":"-1.22","ciUpper":"-0.01","endpoint":"Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)","enrollment":1415}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":10,"regulatoryByCountry":[{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:34:51.767734+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}